期刊文献+

没有处方买到处方药而引发纠纷的案件分析与思考

Analysis and comments on the cases associated with "obtaining prescription drugs without prescription recipe"
原文传递
导出
摘要 药物与人们的生命健康息息相关,也是引发医疗纠纷和诉讼的重要因素。我国目前在保护公众用药安全的制度方面还存在较大的问题,为保护人民用药安全,我国应当尽快出台药品分类管理条例和执业药师法,加快药品分类管理制度和执业药师制度的建设。 As a common sense, drugs play a crucial role in maintaining people's health. Accordingly, It is also a leading cause of diversified medical disputes as well as litigations. Unfortunately, tremendous risks lie in our regimes which function is protecting the public-use of drugs. Therefore, necessary efforts shall be speeded up for the implementation of drug classification system and for deepening licensed pharmacists system structure as well, In order to guarantee the safety and effectiveness of national drugs, statute on drug classification and the licensed pharmacists law should be promoted and eventually passed as soon as possible.
作者 徐敢
出处 《法律与医学杂志》 2005年第3期206-208,共3页 Journal of Law & Medicine
关键词 贺普丁 处方药 执业药师 药品分类管理 Heptodin Prescription drugs Licensed pharmacists Drug classified management
  • 相关文献

参考文献4

二级参考文献24

  • 1Zhang XX, Liu CM, Gong QM, et al. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy. J Gastroenterolo Hepatolo, 2003, 1353-1357.
  • 2Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut, 2000, 46: 562-568.
  • 3Maria Buti, Rafael Esteban. Entecavir, FTC, L-RMAU, LdT and others. J Hepatol, 2003, 39: S139-S142.
  • 4Kirishima T, Okanoue T, Daimon Y, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol, 2002, 37: 259-265
  • 5Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol, 2003, 18: 239-245.
  • 6The EASL Jury. EASL international consensus conference on hepatitis B. J Hepatol, 2003, 38: 533-540.
  • 7Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology, 2001, 34: 1225-1241.
  • 8Li LL, Chun TW, Yin ML, et al. Prophylactic lamivudine prevents hepatitis B reactivation and mortality in patients receiving immunosuppression and chemotherapy. Hepatology, 2000, 32(Pt 2): 1183.
  • 9Liaw YF, Sung JJY, Chow WC, et al. Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blined placebo-controlled clinical trial. Hepatology, 2003, 38(Suppl)1: 262A.
  • 10Fontana RJ. Mangement of patients with decompensated HBV cirrhosis. Seminars in liver disease. 2003 23: 89-100.

共引文献256

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部